Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis (opens in new tab)

BackgroundAt present, there are no approved pharmacological treatments for people at clinical high risk for psychosis (CHR-P). We sought to assess the acceptability of cannabidiol (CBD): a promising candidate treatment for this population.MethodsCHR-P individuals completed a survey which assessed their views on the acceptability of CBD, its expected effectiveness and side effects, and on formulation preferences.ResultsThe sample comprised 55 CHR-P individuals (24.3 [19-34] years and 69% femal...